Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 2, 2001, Pages 426-433

  Zhang, Yilong ^a   Song, Saeheum ^a   Yang, Fan ^a   Au, Jessie L S ^a   Guillaume Wientjes, M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; DOXORUBICIN; SURAMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR GROWTH;

ALGORITHMS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CULTURE MEDIA, CONDITIONED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SURAMIN; TUMOR CELLS, CULTURED;

EID: 0034761804     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Suramin in hormone resistant metastatic prostatic cancer: Significant anticancer activity but unanticipated toxicity
2. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention
3. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin
4. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein
5. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice
6. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation
7. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
8. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells
9. Megestrol acetate in relapsed carcinoma of the prostate
10. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells
11. Suramin sodium
12. Suramin in combination with 5-flucrouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+ LV-based chemotherapy
13. Clinical trials of P-glycoprotein reversal in solid tumours
14. Principles of cancer biology: Biology of cancer metastasis
15. Modulation of tumor cell response to chemotherapy by the organ environment
16. Acute renal toxicity associated with suramin in the treatment of prostate cancer
17. Pharmacodynamics of taxol in human head and neck tumors
18. Blockade of autocrine stimulation in simian sarcoma virus transformed cells reverses down-regulation of platelet-derived growth factor receptors
19. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques
20. Hormonal therapy for stage D cancer of the prostate
21. Circulating glycosaminoglycan anticoagulants associated with suramin treatment
22. Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint
23. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer
24. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms
25. Mineralocorticoid insufficiency due to suramin therapy
26. Suramin-induced polyneuropathy
27. Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and possible neuroprotective mechanism of basic fibroblast growth factor
28. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma
29. Cancer of the prostate
30. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin
31. Carcinoma of the prostate
32. Decetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
33. Suramin interferes with the binding of insulin-like growth factor I (IGF-I) to human osteosarcoma cells and blocks IGF-I stimulated proliferation
34. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells
35. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study
36. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin
37. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
38. Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs
39. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer
40. Differential effect of taxol in rat primary and metastatic prostate tumors: Site-dependent pharmacodynamics